Adjuvant Chemoradiation Therapy for Pancreatic Adenocarcinoma: Who Really Benefits?
Authors:
- Jennifer RymerJRJennifer Rymer
- Elizabeth A.S. KoehlerEKElizabeth A.S. Koehler
- Daniel G. AyersDADaniel G. Ayers
- Jason CastellanosJCJason Castellanos
- David A. KoobyDKDavid A. Kooby
- Sharon H. WeberSWSharon H. Weber
- Clifford S. ChoCCClifford S. Cho
- Max C. SchmidtMSMax C. Schmidt
- Atilla NakeebANAtilla Nakeeb
- Jesus M. MatosJMJesus M. Matos
- Charles R. ScogginsCSCharles R. Scoggins
- 1 May 2009
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 208 (5) , 829-838
Abstract
The role of adjuvant chemoradiation therapy (CRT) in pancreatic cancer remains controversial. The primary aim of this study was to determine if CRT improved survival in patients with resected pancreatic cancer in a large, multiinstitutional cohort of patients. Patients undergoing resection for pancreatic adenocarcinoma from seven academic medical institutions were included. Exclusion criteria included patients with T4 or M1 disease, R2 resection margin, preoperative therapy, chemotherapy alone, or if adjuvant therapy status was unknown. There were 747 patients included in the initial evaluation. Primary analysis was performed between patients that had surgery alone (n=374) and those receiving adjuvant CRT (n=299). Median followup time was 12.2 months and 14.5 months for survivors. Median overall survival for patients receiving adjuvant CRT was significantly longer than for those undergoing operation alone (20.0 months versus 14.5 months, p=0.001). On subset and multivariate analysis, adjuvant CRT demonstrated a significant survival advantage only among patients who had lymph node (LN)-positive disease (hazard ratio 0.477, 95% CI 0.357 to 0.638) and not for LN-negative patients (hazard ratio 0.810, 95% CI 0.556 to 1.181). Disease-free survival in patients with LN-negative disease who received adjuvant CRT was significantly worse than in patients who had surgery alone (14.5 months versus 18.6 months, p=0.034). This large multiinstitutional study emphasizes the importance of analyzing subsets of patients with pancreas adenocarcinoma who have LN metastasis. Benefit of adjuvant CRT is seen only in patients with LN-positive disease, regardless of resection margin status. CRT in patients with LN-negative disease may contribute to reduced disease-free survival.Keywords
This publication has 16 references indexed in Scilit:
- Analysis of Fluorouracil-Based Adjuvant Chemotherapy and Radiation After Pancreaticoduodenectomy for Ductal Adenocarcinoma of the Pancreas: Results of a Large, Prospectively Collected Database at the Johns Hopkins HospitalJournal of Clinical Oncology, 2008
- Adjuvant Radiotherapy and Chemotherapy for Pancreatic Carcinoma: The Mayo Clinic Experience (1975-2005)Journal of Clinical Oncology, 2008
- Adjuvant Therapy for Adenocarcinoma of the Pancreas: Analysis of Reported Trials and Recommendations for Future ProgressAnnals of Surgical Oncology, 2008
- Evaluating the Impact of a Single-Day Multidisciplinary Clinic on the Management of Pancreatic CancerAnnals of Surgical Oncology, 2008
- Impact of Resection Status on Pattern of Failure and Survival After Pancreaticoduodenectomy for Pancreatic AdenocarcinomaAnnals of Surgery, 2007
- One Thousand Consecutive PancreaticoduodenectomiesAnnals of Surgery, 2006
- Cancer Statistics, 2006CA: A Cancer Journal for Clinicians, 2006
- Adjuvant Treatment for Resectable Pancreatic CancerJournal of Clinical Oncology, 2005
- A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic CancerNew England Journal of Medicine, 2004
- Prognostic Factors Following Curative Resection for Pancreatic AdenocarcinomaAnnals of Surgery, 2003